ArticleAnnals of surgical oncology2026
Combined RAS and SMAD4 Mutations and Microsatellite Instability Predict Outcomes in Colorectal Lung Metastases Treated with Image-Guided Thermal Ablation.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundImage-guided thermal ablation (IGTA) is a minimally invasive alternative to colorectal cancer lung metastases (CRLM) for non-surgical candidates. This study evaluated whether combined RAS/SMAD4 mutational status and microsatellite instability (MSI) predict outcomes after IGTA in CRLM, addressing the current controversy over prognostic biomarkers.
methodsThis multicenter retrospective study analyzed 412 CRLM patients undergoing computed tomography (CT)-guided IGTA (March 2014 to December 2022). The patients were stratified by microsatellite status (MSS vs MSI) and RAS/SMAD4 genotype (concurrent mutations ["double"], single mutation, or wild type). The primary endpoints were local tumor progression (LTP), progression-free survival (PFS), and overall survival (OS).
resultsIn multivariable analysis, poorer OS was independently predicted by maximum lesion diameter ≥20 mm, three or more lesions, synchronous metastases, MSI, and RAS mutation, whereas shorter PFS was predicted by RAS and SMAD4. In MSI tumors, concurrent RAS/SMAD4 double mutations were associated with significantly worse OS and PFS than wild type (both p < 0.05), whereas in MSS tumors, even single RAS or SMAD4 mutations portended inferior survival compared with wild type. Relative to MSS, MSI status was independently associated with higher mortality risk (hazard ratio, 1.67; 95 % confidence interval, 1.16-2.41; p = 0.005).
conclusionConcurrent RAS and SMAD4 alterations and MSI status identify high-risk CRLM patients after IGTA. Integrating these molecular markers into clinical decision-making may enhance risk stratification and guide personalized treatment strategies.
Indexed as
Identifiers
41975044What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.